Fluicell

Fluicell FCF Growth

The Year-over-Year Free Cash Flow Growth of Fluicell (FLUI.ST) as of Nov 20, 2026 is 48.38 %. In the previous year, Year-over-Year Free Cash Flow Growth was 29.63 % — a change of 63.27% (higher).

FCF Growth

48.38 %

YoY

63.27%

Last updated:

Year-over-Year Free Cash Flow Growth of Fluicell is 2025 48.38 % . Year-over-Year Free Cash Flow Growth of Fluicell was 2024 29.63 % . It decreases by 63.27% higher compared to the previous year.

The Fluicell FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-68.28 SEK
Jan 1, 2019
-27.55 SEK
Jan 1, 2020
-0.11 SEK
Jan 1, 2021
-8.45 SEK
Jan 1, 2022
-14.25 SEK
Jan 1, 2023
-22.76 SEK
Jan 1, 2024
29.63 SEK
Jan 1, 2025
48.38 SEK
The Fluicell FCF Growth history
YEARFCF GrowthYoY
48.38 %+63.27%
29.63 %-230.19%
-22.76 %+59.68%
-14.25 %+68.75%
-8.45 %+7,849.45%
-0.11 %-99.61%
-27.55 %-59.65%
-68.28 %+38.49%
-49.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Year-over-Year Free Cash Flow Growth of Fluicell is 48.38 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Fluicell since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Fluicell

All Key Metrics — Fluicell